Skip to content

Gas Exchange Derangement Physiopathology in Critically Ill Patients With COVID-19

Gas Exchange Derangement Physiopathology and Response to Different Levels of Positive End-expiratory Pressure in Critically Ill Patients With COVID-19

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05132933
Enrollment
14
Registered
2021-11-24
Start date
2021-10-01
Completion date
2022-12-30
Last updated
2024-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Failure

Brief summary

The study was designed to understand the pathophysiology of gas exchange derangement in critically ill patients with COVID-19. Specifically we will evaluate the effect of 3 different levels of positive end-expiratory pressure (PEEP) and two different levels of inspiratory oxygen fraction (FiO2) on gas exchange by analyzing shunt and dead space. Furthermore, complete respiratory mechanics and distribution of ventilation and perfusion by electrical impedance tomography will be assessed at each level of PEEP.

Interventions

PROCEDUREPEEP trial - Electrical Impedance Tomography

Three different levels of PEEP and two different levels of FiO2 will be tested without changing anything else in the baseline patient ventilation

Sponsors

Policlinico Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients admitted in intensive care unit for COVID-19 related Acute Respiratory Distress Syndrome (ARDS) requiring invasive mechanical ventilation

Exclusion criteria

* Pregnancy * Hemodynamic instability (80-90 mmHg increase or 30-40 mmHg decrease systolic arterial pressure compared to baseline value or need of vasopressors to maintain systolic blood pressure higher than 85 mmHg or electrocardiogram evidence of ischemia/arrhythmias) * Presence of pneumothorax and/or pneumomediastinum * Contraindications to Electrical Impedance Tomography (pacemaker, implantable cardioverter defibrillator, thoracic drainages)

Design outcomes

Primary

MeasureTime frameDescription
Shunt at three different levels of positive end expiratory pressure (PEEP)30 minutes after change of positive end expiratory pressure (PEEP) levelShunt measured by arterial and mixed venous blood samples at each level of PEEP

Secondary

MeasureTime frameDescription
Dead space at three different levels of positive end expiratory pressure (PEEP)30 minutes after change of positive end expiratory pressure (PEEP) levelDead space measured by capnography at each level of PEEP
Shunt and dead space at two different levels of inspiratory oxygen fraction for each level of positive end expiratory pressure (PEEP)30 minutes after change of positive end expiratory pressure (PEEP) levelShunt measured by arterial and mixed venous blood samples and dead space measured by capnography at each level of PEEP
Ventilation/perfusion at three different levels of positive end expiratory pressure (PEEP) assessed by electrical impedance tomography (EIT)30 minutes after change of positive end expiratory pressure (PEEP) levelVentilation/perfusion assessed by Electrical Impedance Tomography at each level of PEEP
Respiratory mechanics at three different levels of positive end expiratory pressure (PEEP)30 minutes after change of positive end expiratory pressure (PEEP) levelRespiratory mechanics (including esophageal pressure measurement) assessed at each level of PEEP by performing end-inspiratory and end-expiratory pauses

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026